We are proud to announce that MedAlliance has chosen to rely on our decidemedical platform for its Selution DeNovo Study, which is the world’s lagest DEB study ever conducted. With the help of our web-based platform decidemedical, the participating sites located all over the world can hand in their medical data and images (DICOM) associated with approximately 3,300 patients for review and valuation in a GDPR-compliant manner.
MedAlliance is an innovative, privately-owned medical technology company specialized in the development and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company has its headquarter in Nyon with further offices located in Germany, UK, USA and the Republic of Singapore.
We are very pleased to be able to contribute to such an important clinical trial with our secure and efficient online technology!
If you want to learn more, you can read our related press release here: